Cone Rod Dystrophy Market Size in the 7MM is expected to grow by 2032 | DelveInsight.
| Published date | 17 April 2024 |
M2 PRESSWIRE-April 17, 2024-: Cone Rod Dystrophy Market Size in the 7MM is expected to grow by 2032 | DelveInsight
(C)1994-2024 M2 COMMUNICATIONS
RDATE:16042024
DelveInsight's "Cone Rod Dystrophy Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Cone Rod Dystrophy, historical and forecasted epidemiology as well as the Cone Rod Dystrophy market trends in the United States, EU4 (Germany, Spain, Italy, France) and the United Kingdom, and Japan.
Key Takeaways from the Cone Rod Dystrophy Market Research Report
*The increase in Cone Rod Dystrophy Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM. *As per DelveInsight analysis, the Cone Rod Dystrophy market is anticipated to witness growth at a considerable CAGR. *The leading Cone Rod Dystrophy Companies working in the market include SparingVision, Pixium Vision SA, Dompe Farmaceutici S.p.A, MD Stem Cells, and others. *Promising Cone Rod Dystrophy Pipeline Therapies in the various stages of development include rhNGF 60 [micro sign]g/ml eye drops solution, SPVN06, and others. *December 2023: Dompe Farmaceutici S.p.A announced a study of Phase 1 & 2 clinical trials for rhNGF 60 [micro sign]g/ml eye drops solution. The primary objective of the study is to assess the safety and tolerability of two dose regimens of recombinant human nerve growth factor (rhNGF) eye drops solution administered over 6 months versus a vehicle control in patients with typical retinitis pigmentosa. The secondary objective of this study is to attempt to show a dose response by assessing the potential efficacy of the rhNGF dose regimens for improving or slowing the deterioration of visual function outcomes at 3 and 6 months. *June 2023: SparingVision announced a study of Phase 1 & 2 clinical trials for SPVN06. This is a two-step, multicenter, Phase I/II study including an open-label dose-escalation phase (Step 1) and a three-arm controlled double-masked randomized extension phase (Step 2), in subjects with advanced RCD due to a mutation in the RHO, PDE6A, or PDE6B gene.
Discover which therapies are expected to grab the Cone Rod Dystrophy Market Share @ Cone Rod Dystrophy Market Outlook
Cone Rod Dystrophy Overview
Cone-rod dystrophy is a group of inherited eye disorders that affect the cone and rod cells of the retina. These cells are photoreceptors responsible for vision; cones handle color vision and work...
To continue reading
Request your trial